Bioconnect Systems to Present First-in-Man Data for Novel Vascular Connector at In3 East Conference on October 19, 2006.

Bioconnect Systems, Inc. to Report First-in-Man Data for Vascular Access in Hemodialysis Patients

AMBLER, Pa. -- Bioconnect Systems (www.bioconnectsystems.com) will present First-in-Man data for its Optiflow[TM] vascular connector during the In3 conference in Boston on October 19. Bioconnect's minimally invasive technology enables surgeons to create precisely controlled anastomoses throughout the human body.

According to David Deaton, MD, FACS Associate Professor of Surgery & Chief, Endovascular Surgery, Georgetown Hospital, "The ability to quickly create a precise anastomosis with a defined cross sectional area gives the surgeon unprecedented control over flow characteristics. Similar to a drug eluting stent's ability to prevent intimal hyperplasia, the Optiflow offers control over local healing, addressing one of the major limitations inherent to hand-sewn anastomoses."

Bioconnect's initial product, the Optiflow [TM] AV, addresses the need for improved vascular access in about 1.9 million worldwide patients suffering from end stage renal disease (ESRD). The Optiflow enables surgeons to create permanent access in dialysis patients by connecting the artery to the vein (AV fistula) or improving the performance of traditional synthetic grafts.

Vascular access is considered the Achilles' Heel of hemodialysis, contributing significantly to high mortality rates of 68% at five years. Approximately one-third of access sites fail within the first year despite numerous interventions.

Series A financing of $7 million is being pursued to fund the Company through clinical trials, regulatory approval, and product launch. More information including an on-line demonstration is available at www.bioconnectsystems.com.